

# David M Thomas,,, Fracp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3605905/publications.pdf>

Version: 2024-02-01

188  
papers

14,181  
citations

30070

54  
h-index

21540

114  
g-index

196  
all docs

196  
docs citations

196  
times ranked

20984  
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks. <i>Journal of Telemedicine and Telecare</i> , 2023, 29, 641-647.	2.7	10
2	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. <i>Patient Education and Counseling</i> , 2022, 105, 452-459.	2.2	5
3	Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. <i>Journal of Genetic Counseling</i> , 2022, 31, 96-108.	1.6	2
4	Cancer patient knowledge about and behavioral intentions after germline genome sequencing. <i>Patient Education and Counseling</i> , 2022, 105, 707-718.	2.2	2
5	Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 81-93.	2.8	2
6	Psychological predictors of advanced cancer patients' preferences for return of results from comprehensive tumor genomic profiling. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 725-734.	1.2	2
7	Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. <i>Patient Education and Counseling</i> , 2022, 105, 2206-2216.	2.2	4
8	Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting. <i>European Journal of Human Genetics</i> , 2022, 30, 930-937.	2.8	6
9	<i>In vitro</i> and <i>in vivo</i> drug screens of tumor cells identify novel therapies for high-risk child cancer. <i>EMBO Molecular Medicine</i> , 2022, 14, e14608.	6.9	12
10	Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions. <i>Public Health Genomics</i> , 2022, 25, 70-79.	1.0	2
11	Using whole-genome sequencing to characterize clinically significant blood groups among healthy older Australians. <i>Blood Advances</i> , 2022, 6, 4593-4604.	5.2	1
12	Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665.	30.7	125
13	Psychological predictors of cancer patients' and their relatives' attitudes towards the return of genomic sequencing results. <i>European Journal of Medical Genetics</i> , 2022, 65, 104516.	1.3	2
14	Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results. <i>Health Psychology</i> , 2022, 41, 396-408.	1.6	1
15	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	51
16	Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. <i>Supportive Care in Cancer</i> , 2022, 30, 8201-8210.	2.2	1
17	Germline RET variants underlie a subset of paediatric osteosarcoma. <i>Journal of Medical Genetics</i> , 2021, 58, 20-24.	3.2	7
18	Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. <i>Patient Education and Counseling</i> , 2021, 104, 944-952.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: "Another piece of the pie". <i>Journal of Genetic Counseling</i> , 2021, 30, 849-860.	1.6	13
20	The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey. <i>Oncotarget</i> , 2021, 12, 2169-2176.	1.8	2
21	ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. <i>Genome Medicine</i> , 2021, 13, 32.	8.2	36
22	Disparities in Cancer Care: The Example of Sarcoma" In Search of Solutions for a Global Issue. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 405-411.	3.8	3
23	Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. <i>Genome Biology</i> , 2021, 22, 109.	8.8	20
24	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
25	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. <i>Leukemia</i> , 2021, 35, 3245-3256.	7.2	32
26	Fear of cancer recurrence in patients undergoing germline genome sequencing. <i>Supportive Care in Cancer</i> , 2021, 29, 7289-7297.	2.2	2
27	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. <i>Npj Precision Oncology</i> , 2021, 5, 58.	5.4	5
28	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. <i>Psycho-Oncology</i> , 2021, 30, 1920-1929.	2.3	0
29	Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2021, 3, e059.	0.5	1
30	Novel RET Fusion <i>RET-SEPTIN9</i> Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. <i>JCO Precision Oncology</i> , 2021, 5, 1160-1165.	3.0	7
31	PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. <i>Cancer Reports</i> , 2021, 4, e1327.	1.4	8
32	Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1212-1217.	4.9	3
33	Who should access germline genome sequencing? A mixed methods study of patient views. <i>Clinical Genetics</i> , 2020, 97, 329-337.	2.0	3
34	Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. <i>Cancer Research</i> , 2020, 80, 354-360.	0.9	22
35	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. <i>Nature Medicine</i> , 2020, 26, 1742-1753.	30.7	185
36	Advanced cancer patient preferences for receiving molecular profiling results. <i>Psycho-Oncology</i> , 2020, 29, 1533-1539.	2.3	5

#	ARTICLE	IF	CITATIONS
37	Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer. JAMA Network Open, 2020, 3, e204721.	5.9	7
38	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1190-1203.	6.3	32
39	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. Science, 2020, 368, 1127-1131.	12.6	83
40	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
41	Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling. Translational Oncology, 2020, 13, 100799.	3.7	7
42	Cancer patients' views and understanding of genome sequencing: a qualitative study. Journal of Medical Genetics, 2020, 57, 671-676.	3.2	16
43	The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nature Communications, 2020, 11, 435.	12.8	47
44	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. OncoImmunology, 2020, 9, 1747340.	4.6	101
45	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 38-47.	1.1	11
46	Patient perspectives on molecular tumor profiling: "Why wouldn't you?" BMC Cancer, 2019, 19, 753.	2.6	21
47	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Modern Pathology, 2019, 32, 1772-1785.	5.5	61
48	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	13.7	273
49	Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts. BMC Medical Genetics, 2019, 20, 69.	2.1	2
50	A quantitative model to predict pathogenicity of missense variants in the <i>TP53</i> gene. Human Mutation, 2019, 40, 788-800.	2.5	21
51	Diagnosis of fusion genes using targeted RNA sequencing. Nature Communications, 2019, 10, 1388.	12.8	122
52	Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. Journal of Physical Education and Sports Management, 2019, 5, a003764.	1.2	7
53	Therapeutic implications of germline genetic findings in cancer. Nature Reviews Clinical Oncology, 2019, 16, 386-396.	27.6	39
54	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. Cancer Discovery, 2019, 9, 1511-1519.	9.4	26

#	ARTICLE	IF	CITATIONS
55	Translating genomic risk into an early detection strategy for sarcoma. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 130-136.	2.8	4
56	The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. <i>European Journal of Human Genetics</i> , 2019, 27, 308-316.	2.8	28
57	A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. <i>Personalized Medicine</i> , 2018, 15, 13-24.	1.5	0
58	Optical mapping reveals a higher level of genomic architecture of chained fusions in cancer. <i>Genome Research</i> , 2018, 28, 726-738.	5.5	41
59	Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk. <i>Journal of Genetic Counseling</i> , 2018, 27, 1055-1066.	1.6	6
60	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. <i>BMC Cancer</i> , 2018, 18, 389.	2.6	10
61	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. <i>BMC Cancer</i> , 2018, 18, 454.	2.6	14
62	Genome-wide association study identifies the <i>GLDC</i> / <i>IL33</i> locus associated with survival of osteosarcoma patients. <i>International Journal of Cancer</i> , 2018, 142, 1594-1601.	5.1	31
63	Locally Aggressive Connective Tissue Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 202-209.	1.6	48
64	Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers. <i>Medical Journal of Australia</i> , 2018, 209, 330-332.	1.7	4
65	Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. <i>Medical Journal of Australia</i> , 2018, 209, 354-355.	1.7	35
66	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. <i>Lung Cancer</i> , 2017, 107, 22-35.	2.0	30
67	Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?. <i>Familial Cancer</i> , 2017, 16, 423-432.	1.9	39
68	IFN- $\gamma$ is required for cytotoxic T cell-dependent cancer genome immunoeediting. <i>Nature Communications</i> , 2017, 8, 14607.	12.8	125
69	Estimating <i>TP53</i> Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 837-844.	2.5	14
70	Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. <i>Cancer Research</i> , 2017, 77, 4279-4292.	0.9	31
71	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. <i>JAMA Oncology</i> , 2017, 3, 1634.	7.1	148
72	Surveillance in Germline <i>TP53</i> Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging. <i>JAMA Oncology</i> , 2017, 3, 1735.	7.1	14

#	ARTICLE	IF	CITATIONS
73	Is Li-Fraumeni syndrome really much more common?. Human Mutation, 2017, 38, 1619-1619.	2.5	1
74	Multidisciplinary Approach to Treatment: An Australian Perspective. , 2017, , 461-476.		1
75	Bone Sarcomas in the Adolescent and Young Adult Population. Pediatric Oncology, 2017, , 417-427.	0.5	1
76	Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology, 2016, 6, 7.	2.8	266
77	Diagnosis and Management of Hereditary Sarcoma. Recent Results in Cancer Research, 2016, 205, 169-189.	1.8	4
78	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clinical Sarcoma Research, 2016, 6, 15.	2.3	80
79	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncology, The, 2016, 17, 1261-1271.	10.7	161
80	Atypical Ewing sarcoma breakpoint region 1 fluorescence <i>in situ</i> hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 2016, 69, 1000-1011.	2.9	12
81	Sarcoma and germ-line DICER1 mutations – Authors’ reply. Lancet Oncology, The, 2016, 17, e471.	10.7	1
82	Mouse Models of Tumor Immunotherapy. Advances in Immunology, 2016, 130, 1-24.	2.2	30
83	The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clinical Sarcoma Research, 2016, 6, 3.	2.3	14
84	International survey of awareness of genetic risk in the clinical sarcoma community. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 133-142.	1.1	3
85	Timing and context: important considerations in the return of genetic results to research participants. Journal of Community Genetics, 2016, 7, 11-20.	1.2	9
86	Adding the “medicines” back into personalized medicine to improve cancer treatment outcomes. British Journal of Clinical Pharmacology, 2015, 80, 929-931.	2.4	5
87	Etiologic, environmental and inherited risk factors in sarcomas. Journal of Surgical Oncology, 2015, 111, 490-495.	1.7	25
88	Surveillance recommendations for patients with germline TP53 mutations. Current Opinion in Oncology, 2015, 27, 332-337.	2.4	33
89	“Cancer 2015”: A Prospective, Population-Based Cancer Cohort – Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. Journal of Personalized Medicine, 2015, 5, 354-369.	2.5	8
90	Clinical implications of genomics for cancer risk genetics. Lancet Oncology, The, 2015, 16, e303-e308.	10.7	17

#	ARTICLE	IF	CITATIONS
91	The life history of neochromosomes revealed. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1000698.	0.7	8
92	The growing problem of benign connective tissue tumours. <i>Lancet Oncology</i> , The, 2015, 16, 879-880.	10.7	7
93	A Genome-Wide Scan Identifies Variants in <i>NFIB</i> Associated with Metastasis in Patients with Osteosarcoma. <i>Cancer Discovery</i> , 2015, 5, 920-931.	9.4	88
94	Accepting risk in the acceleration of drug development for rare cancers. <i>Lancet Oncology</i> , The, 2015, 16, e190-e194.	10.7	9
95	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2029-2037.	7.0	209
96	Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. <i>Drug Discovery Today</i> , 2015, 20, 1429-1432.	6.4	1
97	Distinguishing activity from progress. <i>Lancet Oncology</i> , The, 2015, 16, 1586-1588.	10.7	0
98	RB1-mediated cell-autonomous and host-dependent oncosuppressor mechanisms in radiation-induced osteosarcoma. <i>Oncolmmunology</i> , 2014, 3, e27569.	4.6	5
99	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	2.9	90
100	Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling. <i>Cancer Research</i> , 2014, 74, 921-931.	0.9	24
101	Stress-induced cellular adaptive strategies: Ancient evolutionarily conserved programs as new anticancer therapeutic targets. <i>BioEssays</i> , 2014, 36, 552-560.	2.5	9
102	Li-Fraumeni syndrome: cancer risk assessment and clinical management. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 260-271.	27.6	218
103	The Architecture and Evolution of Cancer Neochromosomes. <i>Cancer Cell</i> , 2014, 26, 653-667.	16.8	161
104	Translational biology of osteosarcoma. <i>Nature Reviews Cancer</i> , 2014, 14, 722-735.	28.4	939
105	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. <i>BMC Medical Genomics</i> , 2014, 7, 23.	1.5	200
106	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.	10.7	487
107	Chemical Genetics of Rapamycin-Insensitive TORC2 in <i>S.Âcerevisiae</i> . <i>Cell Reports</i> , 2013, 5, 1725-1736.	6.4	31
108	The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. <i>BMC Cancer</i> , 2013, 13, 585.	2.6	10

#	ARTICLE	IF	CITATIONS
109	Massivelyâ€parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. <i>Journal of Pathology</i> , 2013, 231, 413-423.	4.5	94
110	Genome-wide association study identifies two susceptibility loci for osteosarcoma. <i>Nature Genetics</i> , 2013, 45, 799-803.	21.4	181
111	Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e562-e570.	10.7	30
112	The Hippo pathway and human cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 246-257.	28.4	1,479
113	Multiomics medicine in oncology: assessing effectiveness, costâ€effectiveness and future research priorities for the molecularly unique individual. <i>Pharmacogenomics</i> , 2013, 14, 1405-1417.	1.3	14
114	Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. <i>Sarcoma</i> , 2013, 2013, 1-11.	1.3	29
115	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2303-2312.	1.6	161
116	Next-Generation Sequence Analysis of Cancer Xenograft Models. <i>PLoS ONE</i> , 2013, 8, e74432.	2.5	30
117	Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. <i>Journal of Clinical Investigation</i> , 2013, 123, 5351-5360.	8.2	54
118	High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort. <i>PLoS ONE</i> , 2013, 8, e69026.	2.5	51
119	RANKL, denosumab, and giant cell tumor of bone. <i>Current Opinion in Oncology</i> , 2012, 24, 397-403.	2.4	74
120	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. <i>Journal of Clinical Oncology</i> , 2012, 30, 2334-2339.	1.6	34
121	Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. <i>Oncolmmunology</i> , 2012, 1, 1313-1322.	4.6	11
122	FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor. <i>Cancer Discovery</i> , 2012, 2, 1118-1133.	9.4	297
123	Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone. <i>Clinical Cancer Research</i> , 2012, 18, 4415-4424.	7.0	372
124	Pazopanib for soft-tissue sarcoma: a PALETTE of data emerges. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 431-432.	27.6	7
125	Hereditary and environmental epidemiology of sarcomas. <i>Clinical Sarcoma Research</i> , 2012, 2, 13.	2.3	7
126	Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. , 2012, 136, 153-168.		36



#	ARTICLE	IF	CITATIONS
127	A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 67-78.	2.8	11
128	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer, 2012, 118, 1649-1655.	4.1	222
129	The relationship between unmet needs and distress amongst young people with cancer. Supportive Care in Cancer, 2012, 20, 75-85.	2.2	130
130	Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials. Journal of Clinical Oncology, 2011, 29, 2781-2786.	1.6	61
131	Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma. Journal of Molecular Diagnostics, 2011, 13, 289-296.	2.8	49
132	Liposarcoma: Molecular Genetics and Therapeutics. Sarcoma, 2011, 2011, 1-13.	1.3	146
133	Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma, 2011, 2011, 1-17.	1.3	30
134	Optimising the management of soft tissue tumours. Pathology, 2011, 43, 295-301.	0.6	2
135	Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer, 2011, 11, 93.	2.6	16
136	Novel Approaches to Treatment of Leiomyosarcomas. Current Oncology Reports, 2011, 13, 316-322.	4.0	9
137	Lessons from the deep study of rare tumours. Journal of Pathology, 2011, 224, 306-308.	4.5	5
138	RECK in osteosarcoma. Cancer, 2011, 117, 3517-3528.	4.1	22
139	Counterpoints in cancer: The somatic mutation theory under attack. BioEssays, 2011, 33, 313-314.	2.5	3
140	Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both MDM2 and MDM1 Amplification in Sarcomagenesis. Clinical Cancer Research, 2011, 17, 416-426.	7.0	106
141	The hard and soft sides of cancer programming. BioEssays, 2010, 32, 837-838.	2.5	0
142	Wnts, bone and cancer. Journal of Pathology, 2010, 220, 1-4.	4.5	17
143	Starting an Adolescent and Young Adult Program: Some Success Stories and Some Obstacles to Overcome. Journal of Clinical Oncology, 2010, 28, 4850-4857.	1.6	199
144	Adolescent and Young Adult Oncology: An Emerging Field. Journal of Clinical Oncology, 2010, 28, 4781-4782.	1.6	114

#	ARTICLE	IF	CITATIONS
145	Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2010, 11, 275-280.	10.7	607
146	Safety of denosumab in giant-cell tumour of bone. <i>Lancet Oncology</i> , The, 2010, 11, 815.	10.7	32
147	Parathyroid Hormone-Related Protein Protects against Mammary Tumor Emergence and Is Associated with Monocyte Infiltration in Ductal Carcinoma <i>In situ</i> . <i>Cancer Research</i> , 2009, 69, 7473-7479.	0.9	41
148	Sarcoma in the Young Adult Population: An International View. <i>Seminars in Oncology</i> , 2009, 36, 227-236.	2.2	15
149	Other Targetable Sarcomas. <i>Seminars in Oncology</i> , 2009, 36, 358-371.	2.2	12
150	Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. <i>International Journal of Cancer</i> , 2009, 125, 426-431.	5.1	31
151	Cancer-associated neochromosomes: a novel mechanism of oncogenesis. <i>BioEssays</i> , 2009, 31, 1191-1200.	2.5	12
152	Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1145-1157.	2.4	41
153	Giant cell tumour of bone. <i>Current Opinion in Oncology</i> , 2009, 21, 338-344.	2.4	143
154	Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 837-851.	8.2	244
155	No-Man's Land: Between Paediatric and Adult Medical Oncology. , 2009, , 885-906.		0
156	The distinctive biology of cancer in adolescents and young adults. <i>Nature Reviews Cancer</i> , 2008, 8, 288-298.	28.4	540
157	Molecular Profiling of Non-Small Cell Lung Cancer: Of What Value in Clinical Practice?. <i>Heart Lung and Circulation</i> , 2008, 17, 451-462.	0.4	1
158	Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18402-18407.	7.1	63
159	Towards social connection for young people with cancer. , 2008, , .		9
160	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 105-119.	3.1	7
161	Dendritic cell immunotherapy for stage IV melanoma. <i>Melanoma Research</i> , 2007, 17, 316-322.	1.2	46
162	Adolescents and young adults with cancer: The challenge. <i>Palliative and Supportive Care</i> , 2007, 5, 173-174.	1.0	6

#	ARTICLE	IF	CITATIONS
163	Molecular Pathogenesis of Osteosarcoma. DNA and Cell Biology, 2007, 26, 1-18.	1.9	269
164	RECK is a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer and Metastasis Reviews, 2007, 26, 675-683.	5.9	151
165	Gene expression profiling of sarcomas. Pathology, 2006, 38, 101-102.	0.6	0
166	HES1 Cooperates With pRb to Activate RUNX2-Dependent Transcription. Journal of Bone and Mineral Research, 2006, 21, 921-933.	2.8	55
167	Femoral mesenchymal chondrosarcoma with secondary aneurysmal bone cysts mimicking a small-cell osteosarcoma. Skeletal Radiology, 2006, 35, 311-318.	2.0	5
168	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer, 2006, 6, 295.	2.6	254
169	PPAR $\beta$ -independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer, 2006, 6, 53.	2.6	83
170	Epigenetic modifications in osteogenic differentiation and transformation. Journal of Cellular Biochemistry, 2006, 98, 757-769.	2.6	57
171	Multidisciplinary approach to diagnosis and management of osteosarcoma – a review of the St Vincent's Hospital experience. International Seminars in Surgical Oncology, 2006, 3, 38.	1.1	19
172	A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochemical Journal, 2005, 390, 427-436.	3.7	60
173	An In vivo Tumor Model Exploiting Metabolic Response as a Biomarker for Targeted Drug Development. Cancer Research, 2005, 65, 9633-9636.	0.9	75
174	Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor $\kappa$ B. American Journal of Pathology, 2005, 167, 117-128.	3.8	124
175	Terminal osteoblast differentiation, mediated by runx2 and p27 <sup>KIP1</sup> , is disrupted in osteosarcoma. Journal of Cell Biology, 2004, 167, 925-934.	5.2	198
176	The STATs in cell stress-type responses. Cell Communication and Signaling, 2004, 2, 8.	6.5	41
177	STI-571 inhibits in vitro angiogenesis. Biochemical and Biophysical Research Communications, 2003, 310, 135-142.	2.1	16
178	A role for $\alpha$ V integrin subunit in TGF- $\beta$ 2-stimulated osteoclastogenesis. Biochemical and Biophysical Research Communications, 2003, 307, 1051-1058.	2.1	14
179	Role of the Retinoblastoma Protein in Differentiation and Senescence. Cancer Biology and Therapy, 2003, 2, 124-130.	3.4	96
180	The Retinoblastoma Protein Acts as a Transcriptional Coactivator Required for Osteogenic Differentiation. Molecular Cell, 2001, 8, 303-316.	9.7	343

#	ARTICLE	IF	CITATIONS
181	Medical Research Council Adjuvant Trial in High-Grade Gliomas. Journal of Clinical Oncology, 2001, 19, 3997-3999.	1.6	6
182	Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer. Prostate Journal, 2001, 3, 30-35.	0.2	1
183	Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation. Journal of Bone and Mineral Research, 1999, 14, 342-350.	2.8	156
184	Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. Journal of Clinical Oncology, 1999, 17, 3110-3116.	1.6	393
185	Malignant cerebral glioma. BMJ: British Medical Journal, 1997, 314, 899-899.	2.3	3
186	Altered responsiveness of proximal tubule fluid reabsorption of peritubular angiotensin II in spontaneously hypertensive rats. Journal of Hypertension, 1990, 8, 407-410.	0.5	19
187	A 3-dimensional digitizer using spherical co-ordinates. Australian Dental Journal, 1988, 33, 138-143.	1.5	1
188	Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature, 1987, 326, 697-698.	27.8	276